Two decades in review: Progress in the treatment of mCRPC

Brandon Bernard, Arun A. Azad, Kim N. Chi

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

Original languageEnglish
Pages (from-to)18-23
Number of pages6
JournalOncology Exchange
Volume13
Issue number3
Publication statusPublished - 1 Aug 2014
Externally publishedYes

Keywords

  • Androgen deprivation therapy
  • Androgen receptor antagonist
  • Bone-targeted therapy
  • Chemotherapy
  • Immunotherapy
  • Metastatic castration-resistant prostate cancer
  • Predictive biomarker
  • Radiopharmaceutical

Cite this

Bernard, Brandon ; Azad, Arun A. ; Chi, Kim N. / Two decades in review : Progress in the treatment of mCRPC. In: Oncology Exchange. 2014 ; Vol. 13, No. 3. pp. 18-23.
@article{805a9831f2144a259253d40daf44867f,
title = "Two decades in review: Progress in the treatment of mCRPC",
abstract = "Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.",
keywords = "Androgen deprivation therapy, Androgen receptor antagonist, Bone-targeted therapy, Chemotherapy, Immunotherapy, Metastatic castration-resistant prostate cancer, Predictive biomarker, Radiopharmaceutical",
author = "Brandon Bernard and Azad, {Arun A.} and Chi, {Kim N.}",
year = "2014",
month = "8",
day = "1",
language = "English",
volume = "13",
pages = "18--23",
journal = "Oncology Exchange",
issn = "1705-2394",
publisher = "Parkhurst Publishing",
number = "3",

}

Bernard, B, Azad, AA & Chi, KN 2014, 'Two decades in review: Progress in the treatment of mCRPC' Oncology Exchange, vol. 13, no. 3, pp. 18-23.

Two decades in review : Progress in the treatment of mCRPC. / Bernard, Brandon; Azad, Arun A.; Chi, Kim N.

In: Oncology Exchange, Vol. 13, No. 3, 01.08.2014, p. 18-23.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Two decades in review

T2 - Progress in the treatment of mCRPC

AU - Bernard, Brandon

AU - Azad, Arun A.

AU - Chi, Kim N.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

AB - Between the mid-1990s and now, median overall survival for men with metastatic castrate resistant prostate cancer (CRPC) starting on chemotherapy has risen from 1 year to almost 3 years. This review summarizes progress made over the last 2 decades in the systemic management of patients with CRPC and evolving treatment directions.

KW - Androgen deprivation therapy

KW - Androgen receptor antagonist

KW - Bone-targeted therapy

KW - Chemotherapy

KW - Immunotherapy

KW - Metastatic castration-resistant prostate cancer

KW - Predictive biomarker

KW - Radiopharmaceutical

UR - http://www.scopus.com/inward/record.url?scp=85043216743&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 18

EP - 23

JO - Oncology Exchange

JF - Oncology Exchange

SN - 1705-2394

IS - 3

ER -